Understanding Reimbursement Changes and Enforcement Initiatives Relevant to Generic Drugs

April 30, 2014 1:30pm

Susan Pilch
Vice President Policy and Regulatory Affairs
National Community Pharmacists Association

Larri A. Short
Arent Fox LLP (Washington, DC)

• Update of CMS Developments –NADACs, FULS, and State Requirements Regarding Changes to FFS Medicaid Reimbursement Algorithms
• Best practices to take away from new litigation over drug approval status and product drug set up in DDR
– Louisiana
– Other possible issues
• What do new pricing statics mean for the AWP risk?
– Will there be a continuing role for WAC and/or AWP?